SciBase reported a 46% increase in net sales for Q1 2025, reaching SEK 8.86 million compared to SEK 6.06 million in the same period last year. The company also saw strong repeat electrode sales, up 20%, and a 30% increase in total electrode volume, highlighting growing clinical adoption of its Nevisense technology. Notably, U.S. skin cancer market sales rose by 306%, showcasing the traction gained in a key global market. Meanwhile, gross margin held steady at 70.5%, reflecting continued cost discipline amid expansion.

The quarter was marked by strategic milestones that bolster SciBase’s positioning in skin diagnostics. Nevisense was included in updated German S1 imaging guidelines as a tool for detecting melanoma and non-melanoma skin cancers, reinforcing its clinical relevance. Furthermore, the company announced that the Mayo Clinic would pilot Nevisense, a significant endorsement from a top-tier U.S. hospital. After the reporting period, SciBase launched the next-generation Nevisense V, an advancement expected to drive deeper market penetration through improved functionality.

Despite reporting a wider loss after tax of SEK 27.5 million, compared to SEK 10.9 million in Q1 2024, and negative operating cash flow of SEK 26 million, SciBase's continued investment in growth and innovation is yielding positive momentum. The strong sales trajectory, deeper U.S. market expansion, and the introduction of Nevisense V set the stage for future gains. With increased equity/assets ratio and improved cash reserves, the company remains focused on scaling its footprint and solidifying its position in the global dermatological diagnostics space.

MedTech Spectrum's Summary

Strong Market Expansion and Adoption - SciBase achieved a 46% increase in net sales, driven by a 306% growth in the U.S. skin cancer market and a 30% rise in electrode sales, signaling increasing global adoption of its diagnostic technology.

Clinical and Regulatory Validation-Nevisense was included in Germany’s updated S1 imaging guidelines for melanoma and non-melanoma skin cancer detection, and the Mayo Clinic initiated a pilot, strengthening the device’s credibility in top-tier medical settings.

Launch of Next-Generation Technology - The company introduced Nevisense V, the next-generation version of its core diagnostic platform, aiming to improve clinical performance and expand usage across dermatology practices internationally.